The antidepressant debate and the balanced placebo trial design: An ethical analysis

International Journal of Law and Psychiatry

Volumn 31, Issue 6, 2008, Pages 453-462

  Waring, Duff R ^a  

^a YORK UNIVERSITY   (Canada)

Author keywords

Active placebos; Antidepressant debate; Deception; Drug effects; Expectancy; Experimental subordination; Placebo effects; Trial design

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO;

ARTICLE; BALANCED PLACEBO TRIAL DESIGN; DRUG EFFECT; DRUG EFFICACY; EXPERIMENTAL DESIGN; HUMAN; MEDICAL ETHICS; PLACEBO EFFECT;

ANTIDEPRESSIVE AGENTS; DRUG THERAPY; ETHICS, CLINICAL; HUMANS; PSYCHIATRY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES;

EID: 56249142803     PISSN: 01602527     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijlp.2008.09.001     Document Type: Article

References (55)

1. Alexander A., and Sherwin E. Deception in morality and law. Law and Philosophy 22 (2003) 393-450
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM-IV-TR fourth edition (text revision) (2000), American Psychiatric Publishing Inc, Washington, DC
3. Anderson I.M., and Haddad P. Clinical trials of antidepressant medications are producing meaningless results. The British Journal of Psychiatry 183 (2003) 102-104
4. Bok S. Lying: Moral choice in public and private life (1999), Vintage Books, New York
5. Brown W.A. Are antidepressants as ineffective as they look?. Prevention and Treatment 5 (2002). http://journals.apa.org/prevention/ Article 25. (Retrieved July19, 2007 from http://journals.apa.org/prevention/ volume5)
6. Councils for International Organizations of Medical Sciences. International ethical guidelines for biomedical research involving human subjects (2002), CIOMS, Geneva
7. Elliott C. A philosophical disease (1999), Routledge, New York
8. Emmanuel E.J., Wendler D., and Grady C. What makes clinical research ethical?. Journal of the American Medical Association 283 (2000) 2701-2711
9. Fergusson D., Glass K.C., Waring D., and Shapiro S. Turning a blind eye: The success of blinding reported in a random sample of randomised, placebo-controlled trials. British Medical Journal 328 (2004) 432-434
10. Fisher S., and Greenberg R.P. How sound is the double-blind design for evaluating psychotropic drugs?. Journal of Nervous and Mental Disease 181 (1993) 345-350
11. Fisher S., and Greenberg R.P. Mood mending medicines: Probing drug, psychotherapy, and placebo solutions. In: Fisher S., and Greenberg R.P. (Eds). From placebo to panacea: Putting psychiatric drugs to the test (1997), John Wiley and Sons, New York 115-172
12. Frances A., and Ross R. DSM-IV-TR case studies: A clinical guide to differential diagnosis (2005), American Psychiatric Publishing Inc, Washington, DC
13. Freedman B. Placebo-controlled trials and the logic of clinical purpose. IRB: A Review of Human Subjects Research 12 6 (1990) 1-6
14. Freedman B., Fuks A., and Weijer C. Demarcating research and treatment: A systematic approach for the analysis of the ethics of clinical research. Clinical Research 40 (1992) 653-660
15. Freedman B., Glass K.C., and Weijer C. Placebo orthodoxy in clinical research: Exposing the myths, 2: Ethical, legal and regulatory myths. Journal of Law, Medicine, and Ethics 24 (1996) 252-259
16. Gaudiano B.A., and Herbert J.D. Antidepressant-placebo debate in the media: Balanced coverage or placebo hype?. The Scientific Review of Mental Health Practice 2 1 (2003) 74-77
17. Gaudiano B.A., and Herbert J.D. Methodological issues in clinical trials of antidepressant medications: Perspectives from psychotherapy. Psychotherapy and Psychosomatics 74 (2005) 17-25
18. Greenberg R.P., Bornstein R.F., Greenberg M.D., and Fisher S. A meta-analysis of antidepressant outcome under 'blinder' conditions. Journal of Consulting and Clinical Psychology 60 (1992) 664-669
19. Halushka v. University of Saskatchewan (1965), 53 D.L.R. (2d) 436 (Sask. C.A.).
20. Healy D. The antidepressant era (1997), Harvard University Press, Cambridge
21. Hull J.G., and Bond C.F. Social and behavioral consequences of alcohol consumption and expectancy: A meta-analysis. Psychological Bulletin 99 (1986) 347-360
22. Khan A., Leventhal R.M., Khan S., and Brown W.A. Severity of depression and response to antidepressants and placebo: An analysis of the Food and Drug Administration database. Journal of Clinical Psychopharmacology 22 (2002) 40-45
23. Kiene H. A critique of the double-blind clinical trial, part 1. Alternative Therapies 2 1 (1993) 74-80
24. Kiene H. A critique of the double-blind clinical trial, part 2. Alternative Therapies 2 2 (1993) 59-64
25. Kienle G.S., and Kiene H. The powerful placebo effect: Fact or fiction?. Journal of Clinical Epidemiology 50 (1997) 1311-1318
26. King D. Debatable forms of consent. Boston Globe (1998, November 16) A1
27. Kirsch I. Are drug and placebo effects in depression additive?. Biological Psychiatry 47 (2000) 733-773
28. Kirsch I., and Antonuccio D. Antidepressants versus placebos: Meaningful advantages are lacking. Psychiatric Times 19 (2002) 9
29. Kirsch I., and Moore T.J. Antidepressants and placebos: Secrets, revelations and unanswered questions. Prevention and Treatment 5 (2002). http://journals.apa.org/prevention/volume5 Article 33. (Retrieved July 19, 2007 from http://journals.apa.org/prevention/volume5)
30. Kirsch I., Moore T.J., Scoboria A., and Nicholls S. The emperor's new drugs: An analysis of antidepressant medication data submitted to the U.S. food and drug administration. Prevention and Treatment 5 (2002). http://journals.apa.org/prevention/volume5 Article 23. (Retrieved July 19, 2007 from http://journals.apa.org/prevention/volume5)
31. Kirsch I., and Rosadino M.J. Do double-blind studies with informed consent yield externally valid results?. Psychopharmacology 110 (1993) 437-442
32. Kirsch I., and Sapirstein G. Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication. Prevention & Treatment 1 (1998). http://journals.apa.org/prevention/volume1 Article 002a. (Retrieved July 19, 2007 from http://journals.apa.org/prevention/volume1)
33. Kirsch I., and Weixel L.J. Double-blind versus deceptive administration of a placebo. Behavioral Neuroscience 102 2 (1988) 319-323
34. Law Reform Commission of Canada. Biomedical experimentation involving human subjects (1989), Law Reform Commission, Ottawa Working Paper No. 61
35. Lemmens T., and Glass K.C. Research involving humans. In: Downey J., Caufield T., and Flood C. (Eds). Canadian health law and policy. 2nd ed. (2002), Butterworths, Toronto 450-500
36. Marlatt G.A., and Rosenhow D.J. Cognitive processes in alcohol use: Expectancy and the balanced placebo design. In: Mello N.K. (Ed). Advances in substance abuse: Behavioral and biological research (1980), JAI Press, Greenwich, CT 159-199
37. Marshall D.T. The law of human experimentation (2000), Butterworths, Toronto
38. Medical Research Council of Canada. Guidelines on research involving human subjects (1987), Minister of Supply and Services Canada, Ottawa
39. Medical Research Council of Canada, Natural Sciences and Engineering Research Council of Canada, and Social Sciences and Humanities Research Council. Tri-council policy statement: Ethical conduct for research involving humans (2005), Public Works and Government Services Canada, Ottawa
40. Moncrieff J. The antidepressant debate. The British Journal of Psychiatry 180 (2002) 193-194
41. Moncrieff J., and Kirsch I. Efficacy of antidepressants in adults. British Medical Journal 331 (2005) 155-157
42. Moncrieff J., Wessley S., and Hardy R. Meta-analysis of trials comparing antidepressants with active placebos. British Journal of Psychiatry 172 (1998) 227-231
43. Moncrieff J., Wessley S., and Hardy R. Active placebos versus antidepressants for depression (Cochrane Review). The Cochrane Library vol. 1 (2002), Update Software, Oxford
44. National Institute for Clinical Excellence. National clinical practice guideline 23 depression: Management of depression in primary and secondary care (2007), The British Psychological Society and Gaskell, London
45. Newall J.D. The case for deception in medical research. In: Erwin E., Gendin S., and Kleiman L. (Eds). Ethical issues in scientific research: An Anthology (1994), Garland Publishing Inc, New York 141-153
46. Parker G. 'New' and 'old' antidepressants: All equal in the eyes of the lore?. The British Journal of Psychiatry 179 (2001) 95-96
47. Picard E.I., and Robertson G.B. Legal liability of doctors and hospitals in Canada. 3rd ed. (1996), Carswell, Toronto
48. Picard E.I., and Robertson G.B. Legal liability of doctors and hospitals in Canada. 4th ed. (2007), Carswell, Toronto
49. Rabkin J.G., Markowitz J.S., Stewart J.W., McGrath P.J., Harrison W., Quitkin F.J., et al. How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine. Psychiatry Research 19 (1986) 75-86
50. Sharpe G., and Weisstub D. The ethics of deception in biomedical research. Health Law in Canada 16 4 (1996) 101-110
51. Thase M.E. Antidepressant effects: The suit may be small, but the fabric is real. Prevention and Treatment 5 (2002). http://journals.apa.org/prevention/volume5 Article 32. Retrieved July 19, 2007 from http://journals.apa.org/prevention/volume5)
52. Title 45 Code of Federal Regulations Part 46: 46 116(d).
53. Walsh T., Seidman S., Sysko R., and Gould M. Placebo response in studies of major depression: Variable, substantial, and growing. Journal of the American Medical Association 287 (2002) 1840-1847
54. Weiss v. Solomon (1989), 48 C.C.L.T. 280 (Que. Sup. Ct.).
55. Zimmerman M., Mattia J., and Posternak M.A. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?. The American Journal of Psychiatry 159 (2002) 469-473